What is the drug pirfenidone used for?

What is the drug pirfenidone used for?

Pirfenidone is used for the treatment of idiopathic pulmonary fibrosis (scarring of the lungs with an unknown cause). Pirfenidone is in a class of medications called pyridones. It is not known exactly how pirfenidone works to treat idiopathic pulmonary fibrosis.

Does pirfenidone really work?

A recent study confirmed that the use of pirfenidone is associated with a survival benefit. The authors observed that pirfenidone treated patients have a 2.47 years longer life expectancy than IPF patients receiving best supportive care [18].

What is antifibrotic therapy?

Two antifibrotic therapies have been approved for the treatment of IPF: nintedanib and pirfenidone. These drugs slow decline in lung function and reduce the risk of acute respiratory deteriorations, which are associated with very high morbidity and mortality.

How long can pirfenidone be taken?

The dose of pirfenidone may be reduced to three capsules per day (one capsule three times a day). If the rash persists after 7 days pirfenidone should be discontinued for 15 days with re-escalation to the recommended daily dose over a period of 2 weeks.

Can you have alcohol with pirfenidone?

You are advised not to smoke whilst taking pirfenidone. You are advised to avoid grapefruits and grapefruit juice. You can drink a small amount of alcohol with pirfenidone (no more than the recommended number of units a week).

Is pirfenidone approved by FDA?

Basel, 21 January 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has accepted the company’s supplemental New Drug Application (sNDA) and granted Priority Review for Esbriet® (pirfenidone) for the treatment of unclassifiable interstitial lung disease (UILD).

Is Antifibrotic good or bad?

Antifibrotic drugs are effective in slowing functional decline but do not represent a definite “cure”, forcing the clinician to focus on how to consider a clinical response to treatment. Clinical trials have based their results on the longitudinal evaluation of FVC.